Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions

Prostate cancer is the 2nd most common malignancy in the world as well as the leading cancer in male population in Taiwan. The treatment selections of prostate cancer are limited by the uncertainty of its aggressiveness (i.e.: histological graded) and staging before treatment. Although prostate mpMRI has much better ability for detection and localization of prostate cancers than other imaging modalities and diagnostic tests, there is still gap for risk stratifications and treatment selection based on prostate mpMRI findings. Thus, a robust radiomics prediction models based on imaging biomarkers on prostate mpMRI with high prediction accuracy could fill the gap of misclassification of risk stratifications of prostate cancers, guides treatment selections and providing monitoring schedules for treated patients as well as early timely additional treatments (i.e.: target therapy or immunotherapy) for patients with high risk of early recurrence. Furthermore, radiomics could provide consistent information which help in decreasing interobserver and intra-observer variability of interpretating prostate cancer even in the use of PIRADS. In this way, this would save the fee of inappropriate or ineffective treatment and avoid unnecessary time and cost of monitoring low risk patients as well as improve patients' survivals and possibly life-quality as well.

Inclusion criteria

• Aged over 20 years old.
• Suspected or confirmed prostate cancer.
• Undergoing prostate mpMRI before clinical treatment.
• Normal renal function(i.e.: estimated GFR ≧60).
• No allergy history to gadolinium based contrast agent.
• Agree to participate this study and sign informed consent.

Exclusion criteria

• mpMRI photography not completed.
• mpMRI images are damaged or poor in quality and cannot be interpreted.
• Without pathological examination confirmed prostate cancer.
• Patient withdraw informed consent.